The oral azacitidine/cedazuridine combination was compared with subcutaneous azacitidine in the phase 3 portion of the AZTOUND trial.
|Videos|May 4, 2020
A 68-Year-Old Woman with Metastatic NTRK Fusion-Positive Colon Cancer
Author(s)Cathy Eng, MD, FACP, FASCO
Cathy Eng, MD, FACP, FASCO, reviews the case of a 68-year-old diagnosed with metastatic NTRK fusion-positive colon cancer and shares treatments options.
Advertisement
Case: A 68-Year-Old Woman With Metastatic NTRK Fusion-Positive Colon Cancer
Initial presentation
- A 68-year-old woman presented with a 3-month history of intermittent abdominal pain, and alternating constipation/diarrhea
- PMH/SH: hypertension and hypercholesterolemia, medically managed; colonoscopy at age 50 was unremarkable; never smoker; no family history of cancer
- PE: abdomen tender on deep palpation in the right lower quadrant
Clinical workup
- Labs: Hb 11.9, Hct 32%, MCV 75 fL, CEA 12.8 ng/mL
- Chest/abdominal/pelvic CT showed a 5-cm right sided bowl mass and multiple hepatic lesions, and regional lymphadenopathy
- Colonoscopy revealed a 5-cm mass in the ascending colon, biopsy was taken
- Pathology: grade 3 poorly differentiated adenocarcinoma, with invasion of the submucosa
- Biomarkers: KRAS-wt, NRAS-wt, BRAF-, NTRK+; MSI-H
- Stage TXNXM1; ECOG PS 1
Advertisement
Related to this article
Adding zabilugene almadenorepvec to standard gemcitabine/nab-paclitaxel extends survival and response in newly diagnosed metastatic pancreatic cancer, with manageable safety signals.
Late 2026 FDA oncology rulings may reshape care—from CSF-1R and ALK drugs to oral SERDs and BCMA CAR T breakthroughs.
Resubmitted FDA filing advances off-the-shelf EBV-specific T-cell therapy tab-cel for relapsed EBV+ PTLD after transplant, with longer follow-up.
Resection with cesium-131 tile-based radiation therapy prolonged time to surgical bed recurrence vs resection with stereotactic radiation in the phase 3 ROADS trial.
Degevma was approved for skeletal-related events in adults with bone metastases, giant cell tumor of bone, and the treatment of hypercalcemia of malignancy.
FDA fast-tracks plinabulin plus docetaxel for post-immunotherapy non-squamous NSCLC, as DUBLIN-4 phase 3 targets survival gains.
September brought accelerated approvals in ESR1-mutant breast cancer and HER2-mutant non–small cell lung cancer, a Galleri panel vote, and a withdrawn I-DXd application.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Denosumab Biosimilar Approved For Existing Oncology Indications
2
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
3
Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC
4
Tile-Based Radiation Improves Local Control in Resected Brain Metastases
5